We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

46 hedge funds and large institutions have $121M invested in Akoya BioSciences in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 4546 (+1)

0.23% more ownership

Funds ownership: 32.62%32.85% (+0.23%)

29% less capital invested

Capital invested by funds: $169M → $121M (-$48.4M)

97% less call options, than puts

Call options by funds: $13K | Put options by funds: $396K

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
0.73%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
6
Increased
19
Reduced
15
Closed
5
Calls
$13K
Puts
$396K
Net Calls
-$383K
Net Calls Change
-$383K
Name Holding Trade Value Shares
Change
Change in
Stake
ZIC
26
ZWJ Investment Counsel
Georgia
$220K +$232K +20,000 New
RFC
27
Regions Financial Corp
Alabama
$142K
Bank of America
28
Bank of America
North Carolina
$105K -$47.2K -4,072 -30%
Deutsche Bank
29
Deutsche Bank
Germany
$89K -$487 -42 -0.5%
Barclays
30
Barclays
United Kingdom
$88K +$93.2K +8,038 New
AIG
31
American International Group
New York
$73K -$5.43K -468 -7%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$73K +$406 +35 +0.5%
JP Morgan Chase
33
JP Morgan Chase
New York
$69K +$4.73K +408 +7%
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$63K -$19K -1,641 -22%
AB
35
Amalgamated Bank
New York
$24K +$25.4K +2,189 New
AF
36
Amalgamated Financial
New York
$24K +$25.4K +2,189 New
UBS Group
37
UBS Group
Switzerland
$19K -$10K -866 -33%
SO
38
STRS Ohio
Ohio
$19K
TRCT
39
Tower Research Capital (TRC)
New York
$17K +$5.78K +498 +45%
Simplex Trading
40
Simplex Trading
Illinois
$17K +$18.8K +1,619 New
PCH
41
Polar Capital Holdings
United Kingdom
$14.5K
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$12K -$18.8K -1,619 -58%
AIP
43
Ameritas Investment Partners
Nebraska
$7K
Citigroup
44
Citigroup
New York
$5K -$36.5K -3,146 -86%
Osaic Holdings
45
Osaic Holdings
Arizona
$3K +$464 +40 +17%
VA
46
VR Adviser
New York
-$6.12M -400,000 Closed
Two Sigma Investments
47
Two Sigma Investments
New York
-$938K -61,273 Closed
Marshall Wace
48
Marshall Wace
United Kingdom
-$313K -20,439 Closed
Citadel Advisors
49
Citadel Advisors
Florida
-$228K -19,651 Closed
CAPTRUST Financial Advisors
50
CAPTRUST Financial Advisors
North Carolina
-$1K -90 Closed

AKYA Hedge Fund Activity: Q1 2022 in Review

46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q1 2022, worth a combined $121M — down 29% from $169M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AKYA positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 15 trimmed.

The largest buyer was Blue Water Life Science Advisors, adding an estimated $4.38M. The largest seller was VR Adviser, exiting entirely with an estimated $6.12M sold.

  • 46 institutional investors held Akoya BioSciences (AKYA) as of Q1 2022, up from 45 in Q4 2021.
  • Funds reported $121M of Akoya BioSciences stock for Q1 2022, down 29% quarter-over-quarter.
  • 6 funds opened new Akoya BioSciences positions in Q1 2022 and 5 closed out, a net change of +1 holder.
  • The largest Akoya BioSciences buyer in Q1 2022 was Blue Water Life Science Advisors, an estimated $4.38M added.
  • The largest Akoya BioSciences seller in Q1 2022 was VR Adviser, an estimated $6.12M sold.

Based on aggregated 13F filings for Q1 2022.